ストックスクリーナーアプリを入手
65.04
0.73%
0.47
アフターアワーズ：
64.60
-0.44
-0.68%
前日終値:
$64.57
開ける：
$64.72
24時間の取引高:
343.31K
Relative Volume:
0.61
時価総額：
$2.80B
収益：
$451.36M
当期純損益:
$-66.42M
株価収益率:
-40.41
EPS:
-1.6097
ネットキャッシュフロー:
$-22.31M
1週間 パフォーマンス:
+4.75%
1か月 パフォーマンス:
-7.24%
6か月 パフォーマンス:
-4.63%
1年 パフォーマンス:
+35.50%
1日の値動き範囲:
$64.35
$65.99
1週間の範囲:
$59.84
$65.99
52週間の値動き範囲:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
名前
Tarsus Pharmaceuticals Inc
セクター
電話
(949) 409-9820
住所
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
65.04 | 2.78B | 451.36M | -66.42M | -22.31M | -1.6097 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 再開されました | Oppenheimer | Outperform |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Outperform |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-27 | 再開されました | H.C. Wainwright | Buy |
| 2023-11-20 | 開始されました | Goldman | Neutral |
| 2023-07-18 | 開始されました | William Blair | Outperform |
| 2023-05-18 | 開始されました | Guggenheim | Buy |
| 2022-08-01 | 開始されました | Barclays | Overweight |
| 2021-12-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-23 | 開始されました | Oppenheimer | Outperform |
| 2020-11-10 | 開始されました | BofA Securities | Buy |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-11-10 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Tarsus Pharmaceuticals Inc (TARS) 最新ニュース
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Technical Reactions to TARS Trends in Macro Strategies - Stock Traders Daily
Tarsus Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TARS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $88 - GuruFocus
D.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Jennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (TARS) Expected to Announce Earnings on Thursday - MarketBeat
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 - GlobeNewswire
Tarsus Pharmaceuticals (TARS) director gains 1,383 shares from RSU vesting - Stock Titan
Tarsus (NASDAQ: TARS) outlines 2026 proxy votes and executive pay plans - Stock Titan
Tarsus to receive $15M milestone after China approves TP-03 eye therapy - MSN
Universal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Analysts at Oppenheimer - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Perspective Therapeutics (CATX) - The Globe and Mail
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating - marketscreener.com
Trading the Move, Not the Narrative: (TARS) Edition - Stock Traders Daily
Tarsus Pharmaceuticals stock price target cut to $100 by Mizuho on revenue outlook - Investing.com Canada
Tarsus Pharmaceuticals, Inc. $TARS Position Increased by M&T Bank Corp - MarketBeat
Tarsus Pharmaceuticals (TARS) Stock Private Investment (-1.47%) 2026-04-20Trending Momentum Stocks - Xã Vĩnh Công
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Down 16.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Tarsus Pharmaceuticals (TARS) - Eastern Progress
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.9%Here's What Happened - MarketBeat
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-04-13 13:14:16 - baoquankhu1.vn
(TARS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Published on: 2026-04-08 15:20:10 - baoquankhu1.vn
Aug Rallies: Can Tarsus Pharmaceuticals Inc benefit from deglobalization2026 Update & Stepwise Trade Signal Guides - baoquankhu1.vn
Analyst Calls: Is Tarsus Pharmaceuticals Inc still a buy after recent gains2026 Market Trends & Low Risk High Reward Ideas - baoquankhu1.vn
Capricorn Fund Managers Ltd Decreases Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Is Tarsus Pharmaceuticals (TARS) Stock Consolidating | Price at $71.50, Up 1.97%Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai
Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history - Yahoo Finance UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street Zen - MarketBeat
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN) - The Globe and Mail
JPMorgan Chase & Co. Sells 63,420 Shares of Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins - Sahm
How TP-05’s Phase 2 Lyme Prophylaxis Trial Progress Could Impact Tarsus Pharmaceuticals (TARS) Investors - Yahoo Finance
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $90 - Moomoo
Price-Driven Insight from (TARS) for Rule-Based Strategy - Stock Traders Daily
TARS Technical Analysis & Stock Price Forecast - Intellectia AI
Tarsus Pharmaceuticals (TARS) Initiates Phase 2 Trial for Lyme D - GuruFocus
Tarsus Pharmaceuticals, Inc. recently disclosed the latest progress on its leading vaccine candidate under development for Lyme disease. - Bitget
Biopharmaceutical company Tarsus Pharmaceuticals, Inc. announced that its innovative oral tablet TP-05 (lotilaner) for the potential prevention of Lyme disease has dosed the first subject in the Phase 2 clinical trial "Calliope". - Bitget
Tarsus Doses First Participant in Calliope, A Phase 2 - GlobeNewswire
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease - Yahoo Finance
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Published on: 2026-03-30 08:36:12 - baoquankhu1.vn
How China TP-03 Approval and US$15 Million Milestone Could Shape Tarsus Pharmaceuticals (TARS) Investors - Sahm
Vanguard Realignment: Tarsus (NASDAQ: TARS) Ownership Reported as 0% by Parent - Stock Titan
Tarsus Pharmaceuticals Inc (TARS) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):